More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.19B
EPS
-0.16
P/E ratio
--
Price to sales
2.6
Dividend yield
--
Beta
2.487772
Previous close
$22.31
Today's open
$22.77
Day's range
$22.36 - $24.02
52 week range
$10.96 - $24.02
show more
CEO
John W. Hanna
Employees
765
Headquarters
Brisbane, CA
Exchange
NASDAQ Global Market
Shares outstanding
51659481
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,.
Business Wire • May 20, 2026

CareDx Announces Dismissal of 2021 Qui Tam Suit
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company. On April 23, 2026, the United States District Court for the Eastern District of New York issued an order dismissing the matter. Ther.
Business Wire • May 11, 2026

CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
Seeking Alpha • May 4, 2026

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On April 30, 2026, as an inducement material to acceptance of employment with CareDx, 23 new employees were awarded restricted stock units (RSUs) for an aggreg.
Business Wire • May 1, 2026

CareDx Announces First Quarter 2026 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $118 million, an increase of 39% year-over-year Testing services revenue of $91 m.
Business Wire • Apr 28, 2026

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monito.
Business Wire • Apr 28, 2026

CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
CareDx (CDNA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago.
Zacks Investment Research • Apr 28, 2026

CareDx Launches AlloSeq Nano for High-Resolution Rapid HLA Typing
CDNA unveils AlloSeq Nano, delivering high-resolution HLA typing in under 3 hours, aiming to boost transplant diagnostics speed and lab efficiency.
Zacks Investment Research • Apr 21, 2026

CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its participation at the International Society of Heart and Lung Transplantation (ISHLT) 2026 Annual Meeting, taking place April 22–25 in Toronto, Canada. The real-world clinical use and scient.
Business Wire • Apr 21, 2026

CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026. AlloSeq Nano is an inn.
Business Wire • Apr 20, 2026

¹ Disclosures

Open an M1 investment account to buy and sell CareDx Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.